Beijing Sun-Novo Pharmaceutical Research (688621.SH): ABA001 injection received approval for clinical trials of pharmaceuticals

16:00 02/04/2026

Sunshine Pharmaceutical Co., Ltd. (688621.SH) announced that the company and its wholly-owned subsidiary, Beijing Alna Technology Co., Ltd., have received the "Notice of Approval for Clinical Trial of Drugs" issued by the State Food and Drug Administration. The company's application for clinical trials of ABA001 injection has been approved, and ABA001 injection is intended to be indicated for hypertension.

Beijing Sun-Novo Pharmaceutical Research (688621.SH) announced that the company and its wholly-owned subsidiary Beijing Alna Technology Co., Ltd. have received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The clinical trial application for the company's research project ABA001 injection has been approved. The ABA001 injection is intended to be indicated for hypertension.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.

Energy crisis does not hinder the expansion ambition: Microsoft Corporation (MSFT.US) increases investment in Japan by $10 billion, joining forces with SoftBank and Sakura to build AI cloud infrastructure.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.